JP2024507638A5 - - Google Patents

Info

Publication number
JP2024507638A5
JP2024507638A5 JP2023540524A JP2023540524A JP2024507638A5 JP 2024507638 A5 JP2024507638 A5 JP 2024507638A5 JP 2023540524 A JP2023540524 A JP 2023540524A JP 2023540524 A JP2023540524 A JP 2023540524A JP 2024507638 A5 JP2024507638 A5 JP 2024507638A5
Authority
JP
Japan
Prior art keywords
compound
composition
sexual
composition according
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023540524A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507638A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/014075 external-priority patent/WO2022165017A1/en
Publication of JP2024507638A publication Critical patent/JP2024507638A/ja
Publication of JP2024507638A5 publication Critical patent/JP2024507638A5/ja
Priority to JP2026066979A priority Critical patent/JP2026120717A/ja
Pending legal-status Critical Current

Links

JP2023540524A 2021-01-28 2022-01-27 性機能障害処置のための神経刺激性ステロイドの使用 Pending JP2024507638A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026066979A JP2026120717A (ja) 2021-01-28 2026-04-15 性機能障害処置のための神経刺激性ステロイドの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163142840P 2021-01-28 2021-01-28
US202163142833P 2021-01-28 2021-01-28
US63/142,840 2021-01-28
US63/142,833 2021-01-28
PCT/US2022/014075 WO2022165017A1 (en) 2021-01-28 2022-01-27 Use of neuroactive steroids for treatment of sexual dysfunction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026066979A Division JP2026120717A (ja) 2021-01-28 2026-04-15 性機能障害処置のための神経刺激性ステロイドの使用

Publications (2)

Publication Number Publication Date
JP2024507638A JP2024507638A (ja) 2024-02-21
JP2024507638A5 true JP2024507638A5 (cg-RX-API-DMAC7.html) 2025-02-03

Family

ID=80787167

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023540524A Pending JP2024507638A (ja) 2021-01-28 2022-01-27 性機能障害処置のための神経刺激性ステロイドの使用
JP2026066979A Pending JP2026120717A (ja) 2021-01-28 2026-04-15 性機能障害処置のための神経刺激性ステロイドの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026066979A Pending JP2026120717A (ja) 2021-01-28 2026-04-15 性機能障害処置のための神経刺激性ステロイドの使用

Country Status (9)

Country Link
US (1) US20240122945A1 (cg-RX-API-DMAC7.html)
EP (1) EP4284382A1 (cg-RX-API-DMAC7.html)
JP (2) JP2024507638A (cg-RX-API-DMAC7.html)
KR (1) KR20230136599A (cg-RX-API-DMAC7.html)
AU (1) AU2022214187A1 (cg-RX-API-DMAC7.html)
CA (1) CA3206537A1 (cg-RX-API-DMAC7.html)
IL (1) IL304080A (cg-RX-API-DMAC7.html)
MX (1) MX2023008726A (cg-RX-API-DMAC7.html)
WO (1) WO2022165017A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
IL309922A (en) * 2021-07-28 2024-03-01 Sage Therapeutics Inc Crystalline forms of a neuroactive steroid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080080094A (ko) * 2005-10-14 2008-09-02 하. 룬트벡 아크티에 셀스카브 에스시탈로프람 및 부프로피온의 저용량 조합물을 이용한중추신경계 장애의 치료 방법
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
EP3068226A4 (en) * 2013-11-11 2017-05-17 Euthymics Bioscience, Inc. Novel methods
SI3705488T1 (sl) * 2014-05-29 2022-10-28 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporaba le-teh
PH12018501923B1 (en) * 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3612186A1 (en) * 2017-04-18 2020-02-26 Marinus Pharmaceuticals, Inc. Sustained release injectable neurosteroid formulations
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
MX2021010744A (es) * 2019-03-04 2022-01-18 Praxis Prec Medicines Inc Metodos para el tratamiento de la perimenopausia y la menopausia.
US20230210870A1 (en) * 2020-06-08 2023-07-06 Eliem Therapeutics, Inc. Methods of treating female health conditions related to sex hormones

Similar Documents

Publication Publication Date Title
Bartlik et al. Psychostimulants apparently reverse sexual dysfunction secondary to selective serotonin re-uptake inhibitors
Damluji et al. Paradoxical worsening of depressive symptomatology caused by antidepressants
JP2003503450A5 (cg-RX-API-DMAC7.html)
AR069260A1 (es) Compuesto 1-[2-(2, 4-dimetilfenilsulfanil)fenil]piperazina.usos terapeuticos de compuestos que tienen actividad combinada de sert (transportador de serotonina), 5-ht3 (receptor 3 de 5-hidroxitriptamina) y 5-ht1a (receptor 1a de 5-hidroxitriptamina).metodo de tratamiento.
KR20230136599A (ko) 성 기능장애의 치료를 위한 신경활성 스테로이드의용도
JP2024516297A5 (cg-RX-API-DMAC7.html)
JP2024515829A5 (cg-RX-API-DMAC7.html)
AU2004311869A1 (en) Compositions and methods to treat recurrent medical conditions
EP4494701A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
Ryu et al. The effects of auricular acupressure therapy on sleep disorder and fatigue in menopausal women
Power-Smith Beneficial sexual side-effects from fluoxetine
Riley et al. The effect of single dose diazepam on female sexual response induced by masturbation
JP2009502945A (ja) 覚醒を改善する方法
JP2004002474A (ja) 純粋なフルオキセチンのs(+)異性体を用いる組成物
JP2005531594A5 (ja) 慢性痛の治療用トリプルモノアミン再取り込み阻害剤
US6943193B1 (en) Method for treating sexual dysfunction
CN1281222C (zh) 预防和治疗过早射精和/或性兴奋超敏反应的药物组合物
JP2519148B2 (ja) うつ病治療剤
WO2018109935A1 (ja) Ptsd患者において悪夢を予防、改善、又は治療する薬剤
US20140148465A1 (en) Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine
EP0651638A1 (en) Pharmaceutical composition and method of treatment for serotonin depletion illness
Lim Initial Management of the Newly Diagnosed PE Patient
RU2440155C1 (ru) Способ лечения климактерического синдрома
RU2323018C1 (ru) Способ лечения эректильной дисфункции, ассоциированной с гипертонической болезнью, у больных хроническим простатитом
WO2019172737A1 (ru) Способ лечения энцефалопатии